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Abstract
Background: Spinal cord injury (SCI) is a severe neurological disorder with many disabling consequences, including
persistent neuropathic pain, which develops in about 40 % of SCI patients and is induced and sustained by excessive
and uncontrolled spinal neuroinflammation. Here, we have evaluated the effects of lipoxin A4 (LXA4), a member of a
unique class of endogenous lipid mediators with both anti-inflammatory and analgesic properties, on spinal
neuroinflammation and chronic pain in an experimental model of SCI.
Methods: Spinal hemisection at T10 was carried out in adult male CD1 mice and Wistar rats. To test if LXA4 can
reduce neuroinflammation and neuropathic pain, each animal received two intrathecal injections of LXA4 (300 pmol)
or vehicle at 4 and 24 h after SCI. Sensitivity to mechanical stimulation of the hind paws was evaluated using von Frey
monofilaments, and neuroinflammation was tested by measuring the mRNA and/or protein expression levels of glial
markers and cytokines in the spinal cord samples after SCI. Also, microglia cultures prepared from murine cortical tissue
were used to assess the direct effects of LXA4 on microglial activation and release of pro-inflammatory TNF-α.
Results: LXA4 treatment caused significant reductions in the intensity of mechanical pain hypersensitivity and spinal
expression levels of microglial markers and pro-inflammatory cytokines induced by SCI, when compared to rodents
receiving control vehicle injections. Notably, the increased expressions of the microglial marker IBA-1 and of
the pro-inflammatory cytokine TNF-α were the most affected by the LXA4 treatment. Furthermore, cortical microglial
cultures expressed ALX/FPR2 receptors for LXA4 and displayed potentially anti-inflammatory responses upon challenge
with LXA4.
Conclusions: Collectively, our results suggest that LXA4 can effectively modulate microglial activation and TNF-α
release through ALX/FPR2 receptors, ultimately reducing neuropathic pain in rodents after spinal cord hemisection. The
dual anti-inflammatory and analgesic properties of LXA4, allied to its endogenous nature and safety profile, may render
this lipid mediator as new therapeutic approach for treating various neuroinflammatory disorders and chronic pain
with only limited side effects.
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Background
Spinal cord injury (SCI) is a highly debilitating condition
with a worldwide incidence that ranges from 40 to 80
cases per million people per year [1]. SCI is generally as-
sociated with a wide array of comorbidities that typically
require lifelong therapy and rehabilitative care. Thus,
SCI translates not only into enormous personal and fi-
nancial losses for the patient but also into substantial
burdens to national economies and health-care systems.
Pain is a severe problem for many SCI patients. It is esti-
mated that 40 to 50 % of patients with SCI develop neuro-
pathic pain within the first year after injury, a chronic pain
condition resulting from nerve damage [2, 3]. Neuropathic
pain after SCI is characterized by spontaneous persistent
pain and evoked pain, such as mechanical allodynia (pain
evoked by normally non-noxious tactile stimuli) and
thermal hyperalgesia (an increased response to noxious
thermal stimuli) at/or below the level of injury [4]. Unfor-
tunately, clinical management of neuropathic pain is often
ineffective or inadequate, mostly focusing on the modula-
tion of the neuronal activity by targeting neuronal sodium
and calcium channels or NMDA and GABA receptors [5].
However, in recent years, it has become evident that the
development of neuropathic pain involves not only neur-
onal pathways but also components of the immune system
and glial cells, such as astrocytes and microglia, that
mount a local form of inflammation called neuroinflam-
mation [6, 7].
SCI is marked by an extensive neuroinflammation that
is characterized by early activation of microglia and
astrocytes which can release chemokines and cytokines
to enhance the infiltration of peripheral leukocytes into
the spinal cord through the damaged blood-spinal cord
barrier [8]. SCI pathology is reduced, and spontaneous
recovery of neurological function (motor, sensory, and
autonomic) is improved when the activation of glial cells
and/or the recruitment of leukocytes are controlled [9].
Increasing evidence suggests that targeting neuroinflam-
mation may also offer new opportunities for better
management of neuropathic pain [10–12].
Lipoxins and resolvins are endogenous lipid mediators
that contribute to control the inflammatory response and
allow inflamed tissues to return to homeostasis once the
need for inflammation is over [13, 14]. They are potent
anti-inflammatory, pro-resolution, and analgesic media-
tors acting in the picomolar to nanomolar dose range,
which is a desirable characteristic for drug development.
Lipoxins and resolvins can attenuate neuroinflammation
as well as inflammatory and neuropathic pain [15–18].
Due to the robust neuroinflammation and severe
neuropathic pain that characterize SCI, we hypothe-
sized that these lipid mediators may represent a novel
strategy to control both excessive neuroinflammation
and pain after SCI.
Lipoxin A4 (LXA4) is an eicosanoid generated from ara-
chidonic acid via sequential actions of lipoxygenases that
appears to act at both temporal and spatially distinct sites
from other eicosanoids produced during the course of an
inflammatory response, and that, alongside resolvins,
stimulates natural resolution of the process [14]. Further-
more, stable analogs of LXA4 exist on the market and
have shown potent anti-inflammatory and pro-resolution
actions in vitro and in vivo [19]. Intrathecal LXA4 injec-
tions have been shown to quell pain in different animal
models of chronic pain [18, 20, 21]. In particular, it was
observed that LXA4 reduced inflammatory pain through
activation of ALX/FPR2 receptors and blocking of MAPKs
signaling in spinal cord astrocytes [15]. However, the
unique role of LXA4 in neuropathic pain and its control
of microglial signaling are virtually unknown. Therefore,
the present study was designed to explore the possible
anti-inflammatory and analgesic effects of LXA4 after
spinal cord hemisection, a common rodent model of SCI.
Methods
Experiments were performed on male CD1 mice and
Wistar rats. The Institutional Animal Care and Use
Committee of Duke University and the Ethics Committee
on Animal Use of the Universidade Federal de Santa
Catarina approved all animal procedures and experimental
protocols.
Animal surgery and drug administration
Spinal cord injury by left-side hemisection was performed
as described previously [22], with some modifications.
Under general anesthesia with 2–3 % isoflurane in oxygen,
a longitudinal incision was made and a laminectomy was
performed at two vertebral segments, T9–T10. The spinal
cord was then hemisected at T10 on the left side by pla-
cing a 28-gauge needle dorsiventrally at the midline of the
cord and pulling it laterally to ensure the completeness of
the hemisection. Subsequently, the fascia, musculature,
and skin were sutured.
Intrathecal administration of drugs
Intrathecal injections were performed under brief iso-
flurane anesthesia (2.7 %) by spinal cord puncture with a
281/2-G needle connected to a 1-mL insulin syringe. The
needle was inserted perpendicularly between the L4 and
L5 levels of the spinal cord, and injections were given in
a fixed volume of 10 μL. Lipoxin A4 (Cayman Chemicals
Co.) was prepared in 0.5 % ethanol in sterile PBS and
administered intrathecally 4 and 24 h after SCI surgery.
A different group of mice also received a new injection of
LXA4 or vehicle on the 35th day after surgery, according to
Fig. 1a. ALX/FPR2 receptor short-interfering RNA (siRNA)
or scrambled control (OriGene Technologies Inc.) were
mixed with the transfection reagent polyethyleneimine
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(PEI, Fermentas), dissolved in 5 % glucose in RNase-free
water [17]. The protocol for siRNA administration included
two injections: one given at 72 h before surgery and a
second injection given in combination with LXA4 at 4 h
after surgery. At 24 h after surgery (20 h after completion
of siRNA treatment), mice received another injection of
LXA4 alone.
Behavioral analysis
In mice, the mechanical thresholds for 50 % paw
withdrawal were assessed by testing each animal’s
reactions to successive application of multiple caliber
von Frey hairs (vFh) to either hindpaw, using the up-down
method [23]. Rats were evaluated through the estimation
of the frequency of paw withdrawal responses to ten
consecutive applications of a von Frey hair exerting 15g
of force, applied perpendicularly to the ventral surface of
each hindpaw at 30-s intervals. Mice mechanical sensitiv-
ity was assessed before surgery for a baseline estimate and
on the 7th, 14th, 21st, 28th, and 35th days after surgery
and/or treatment with LXA4 or vehicle. On the 35th day,
animals received a new injection of LXA4 and were evalu-
ated at 1, 3, 6, and 24 h post-treatment. For the siRNA-
treated mice, behavioral analysis was performed on the
seventh day after surgery. Rats’ mechanical sensitivity was
assessed before surgery for a baseline estimate and on the
2nd, 7th, 14th, 21st, and 28th days after surgery and/or
treatment with LXA4 or vehicle.
Quantitative real-time RT-PCR (qPCR)
Spinal cord samples were collected 7 days after SCI or
sham surgery. Total RNA was extracted using Direct-zol™
RNA MiniPrep Kit (Zymo Research Corporation) and
reverse-transcribed using the iScript cDNA Synthesis®
Fig. 1 Lipoxin A4 attenuates mechanical allodynia induced by spinal cord hemisection in mice. a Treatment scheme for intrathecal injections of
lipoxin A4 or vehicle and behavioral analyses. b, e Following SCI, adult mice develop mechanical allodynia in both ipsilateral and contralateral hindpaws.
Fifty percent paw withdrawal thresholds are increased with LXA4 administration at 4 and 24 h, compared to vehicle-treated group. An
additional intrathecal bolus injection of 300 pmol of LXA4 at 35 days still attenuated mechanical allodynia in both ipsilateral and contralateral paws
from 3 h up to 24 h. c, f–d, g The area under the curve depicting variations of 50 % paw withdrawal thresholds in time are presented for treatment
evaluation up to 35 days and after the bolus injection. Results are presented as mean ± SEM. Asterisk denotes p < 0.05 when comparing
to sham-operated group and number sign denotes p < 0.05 when comparing to vehicle-treated group (two-way ANOVA followed by
Bonferroni; n = 6 mice/group)
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(Bio-Rad), following the respective protocols provided
with the kits. Specific primers including the housekeeping
control GAPDH were purchased from Sigma-Aldrich
(Table 1). Gene-specific mRNA analysis was performed
using CFX96 Real-Time system (Bio-Rad), and the
relative quantities of mRNAs were calculated using
the comparative Ct method [24, 25].
PCR and gel electrophoresis
The spinal cord, cultured microglia, and astrocytes cDNA
were tested for the presence of the ALX/FPR2 receptor.
Primers for ALX/FPR2 (forward TATAGTGAGAGCCAA
GTA, reverse AATGAGAGCAATCAAGAA) were used
in PCR reactions containing sample cDNA, Taq RED
Master Mix, 2.0X (Apex) 0.2 mM of each primers. A
standard PCR protocol was run in a T100™ Thermal
Cycler (Bio-Rad), and amplified products were
displayed on a SYBR Safe DNA gel stain (Invitrogen)
1 % agarose gel.
Primary cultures of microglia and astrocytes
Astrocyte and microglia cultures were prepared from
cerebral cortexes of 2-day-old postnatal mice, as previ-
ously described [26]. Briefly, tissues were transferred to
ice-cold Hank’s buffer, meninges were carefully removed,
and tissues were triturated and collected by centrifugation.
The cell pellets were dissociated and suspended in a
medium containing 10 % fetal bovine serum in DMEM.
After trituration and filtration, cells were plated into T75
flasks and cultured at 37 °C with 5 % CO2/95 % air.
Medium was replaced every 3–4 days. Confluence was
achieved after 2 weeks, and microglia started to grow over
the astrocytes after 3 weeks. For preparing microglia
cultures, the mixed glial cells were shaken for 4 h, and the
floating cells (microglial pool) were collected and
cultured at a density of 2.5 × 105 cells/ml. This method
resulted in >95 % purity of astrocytes or microglia.
Before performing experiments with astrocytes, we
added 0.15 mM dibutyryl cAMP (Sigma-Aldrich) to
the culture for 2–3 days to induce astrocytic differenti-
ation [27].
For analyzing TNF-α and p-p38 expression, microglia
culture medium was replaced by Opti-MEM medium
(Life Technologies, MA, EUA), containing 1 % penicil-
lin/streptomycin, and cells were incubated with LXA4
(10 or 100 nM) for 30 min prior to IFN-γ (20 ng/mL)
for 3 h.
Western blot
Cells were collected by using RIPA buffer (Thermo
Fisher Scientific), protein concentrations were deter-
mined by BCA Protein Assay (Pierce), and 20 μg of
proteins was loaded for each lane and separated by
SDS-PAGE gel (4–15 %; Bio-Rad). After the transfer,
the blots were incubated overnight at 4 °C with polyclonal
antibody against p-p38 (1:1000, Cell Signaling) or GAPDH
for loading control (1:10000, Millipore). These blots were
further incubated with HRP-conjugated secondary anti-
body, developed in ECL solution (Pierce), and the chemi-
luminescence was revealed by Bio-Rad ChemiDoc XRS
for 1–5 min. Specific bands were evaluated by apparent
molecular sizes. The intensity of the selected bands was
analyzed using NIH Image J software.
Enzyme-linked immusorbent array
Culture medium (Opti-MEM, Life Technologies) was
collected after treatment, and protein concentration was
determined by BCA Protein Assay (Pierce). TNF-α
mouse ELISA kit was purchased from R&D Systems
(R&D Systems, MN, USA). For each assay, 50 μL of
culture medium was used and the standard curve was
included in each experiment.
Rat spinal cord T9 to T11 segments were collected 2, 4,
and 7 days after SCI, and protein concentration was
determined by NanoDrop 1100 (Nanodrop Technologies,
Wilmington, USA). TNF-α, IL-β, IL-6, and IL-10 rat
ELISA kits were also purchased from R&D Systems.
Table 1 Specific primers used for quantitative real-time RT-PCR (qPCR)
Forward primers Reverse primers Accession no.
GAPDH TTGATGGCAACAATCTCCAC CGTCCCGTAGACAAAATGGT NM_001001303
FPR2 CACAGGAACCGAAGAGTGTAAG CACCATTGAGAGGATCCACAG NM_008039
GFAP GAATCGCTGGAGGAGGAGAT GCCACTGCCTCGTATTGAGT NM_010277
IBA1 GGACAGACTGCCAGCCTAAG GACGGCAGATCCTCATCATT NM_019467
P2RY12 TTTCAGATCCGCAGTAAATCCAA GGCTCCCAGTTTAGCATCACTA NM_016928
TNF-α CCCCAAAGGGATGAGAAGTT CACTTGGTGGTTTGCTACGA NM_013693
IL-6 TCCATCCAGTTGCCTTCTTGG CCACGATTTCCCAGAGAACATG NM_031168
iNOS GGAGTGACGGCAAACATGACT TAGCCAGCGTACCGGATGA NM_010927
TGFβ CCACCTGCAAGACCATCGAC CTGGCGAGCCTTAGTTTGGAC NM_011577
IL-10 AGCCGGGAAGACAATAACTG GGAGTCGGTTAGCAGTATGTTG NM_010548
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Immunofluorescence
For the spinal cord IF, mice were deeply anesthetized
with isoflurane and perfused through the ascending
aorta with PBS, followed by 4 % paraformaldehyde with
1.5 % picric acid in 0.16 M phosphate buffer. After the
perfusion, the T9 to T11 spinal cord segments were re-
moved and post-fixed in the same fixative overnight.
Spinal cord sections (30 μm) were cut in a cryostat, and
the sections were first blocked with 2 % goat serum for
1 h at room temperature. The sections were then incu-
bated overnight at 4 °C with the primary antibodies
against Iba-1 (1:1000; Wako Pure Chemical Industries)
and GFAP (1:1000; Millipore). The sections were then in-
cubated for 1 h at room temperature with cyanine 3 (Cy3)-
or FITC-conjugated secondary antibodies (1:400; Jackson
ImmunoResearch). DAPI (Vector laboratories) was used to
stain cell nuclei. The stained and mounted sections were
examined with a Nikon fluorescence microscope, and
images were captured with a CCD SPOTcamera.
Microglia cells were fixed in paraformaldehyde 4 % with
0.1 % picric acid for 20 min and then washed three times
with PBS. Sections were incubated at room temperature
for 30 min in PBS-10 % goat serum (Jackson ImmunoRe-
search) with 2 % bovine albumin (Sigma-Aldrich) and
0.4 % Triton-X100 (Sigma-Aldrich). Primary ALX/FPR2/
FPRL1 antibody (1:200; Novus biologicals) was diluted in
PBS-5 % goat serum (Sigma-Aldrich) with 1 % bovine al-
bumin (Sigma-Aldrich) and 0.2 % Triton-X100 and incu-
bated overnight at 4 °C. Corresponding anti-rabbit Cy3
(Jackson ImmunoResearch) was diluted in PBS containing
2 % goat serum (Sigma-Aldrich), 0.4 % bovine albumin
(Sigma-Aldrich), and 0.08 % Triton-X100 and incubated at
room temperature for 1 h for secondary detection. DAPI
(Life Technologies) was used as counterstaining.
Statistical analysis
All data are expressed as mean ± SEM, unless otherwise
stated. The statistical significance between the groups was
assessed using one or two-way ANOVA followed by the
Bonferroni test or by Student’s paired or unpaired t tests,
as appropriate. The criterion for statistical significance
was p ≤ 0.05. All analyses were done with GraphPad
Prism® 6 software (GraphPad Software Inc., San Diego,
CA, USA).
Results
Lipoxin A4 exerts an antiallodynic effect in mice and rats
after SCI
To investigate if LXA4 blocks pain associated with
SCI, we used the spinal cord thoracic hemisection ro-
dent model of SCI [22]. Typically, this model results
in bilateral persistent below-level pain in mice and
rats, including increase in mechanical allodynia (Fig. 1
and Additional file 1: Figure S1, respectively). Two
intrathecal injections of 300 pmol LXA4, given at 4 and
24 h after SCI (Fig. 1a), exerted antiallodynic effects in
both mice (Fig. 1b, c, e, f ) and rats (Additional file 1:
Figure S1A–D). In mice, the 50 % paw withdrawal thresh-
olds was significantly increased by LXA4 treatment at
7 days after SCI in the contralateral paw only and bilat-
erally at 14 days (ipsilateral paw F(2,8) = 12.41, p = 0.0035;
contralateral paw F(2,8) = 13.80, p = 0.0026), as compared
with the vehicle-treated mice (Fig. 1b, c), and this attenu-
ation of allodynia by LXA4 was maintained for up to
35 days after SCI (Fig. 1e, f ). LXA4 also promoted a simi-
lar bilateral antiallodynic effect from 7 to 28 days after SCI
in rats (Additional file 1: Figure S1).
Because lipoxins are sensitive to metabolic inactivation
by dehydrogenation [14] and neuropathic pain persisted
for at least 5 weeks, we tested whether an additional
single bolus intrathecal injection of 300 pmol of LXA4
at 35 days after SCI (Fig. 1a) could still exert antiallody-
nic effects in mice. Interestingly, this late LXA4
treatment significantly attenuated mechanical allodynia
in both the ipsilateral (F(2,8) = 13.23, p = 0.0029) and
contralateral paws (F(2,8) = 107.2, p < 0.0001) from 3 h
up to 24 h in mice (Fig. 1b, d, e, g).
Lipoxin A4 exerts its antiallodynic effect through ALX/
FPR2 receptors
LXA4 binds with high affinity to a G protein-coupled
ALX/FPR2 receptor [28, 29]. To test whether the antiallo-
dynic effect of LXA4 was mediated through the ALX/FPR2
receptor, we used intrathecal injections of ALX/FPR2
siRNA at 2 days before and on the same day of surgery to
significantly knockdown the expression of ALX/FPR2
receptors by ~50 % in the spinal cord, as compared to the
control non-target siRNA (Fig. 2c). We tested the antiallo-
dynic effect of LXA4 at 7 days after SCI, since the siRNA
effect has a tendency to wear off after 1 week [30]. Treat-
ment with ALX/FPR2 receptor siRNA did not cause any
change to the mechanical sensitivity of the ipsilateral paw
(Fig. 2a), which is consistent with the absence of allodynia
observed at this time point (Fig. 1b). However, SCI-
induced mechanical allodynia in the contralateral paw was
unaffected by LXA4 treatment in mice receiving ALX/
FPR2 siRNA, whereas it was significantly reduced by LXA4
treatment in mice receiving control non-target siRNA
(Fig. 2b). These results suggest that the analgesic effects of
intrathecal LXA4 were mediated, at least in part, through
spinal ALX/FPR2 receptors.
LXA4 decreases the SCI-induced reactivity of microglial
cells, but not astrocytes
Because LXA4 has been shown to target glial cells
[31–33] and these cells play important roles in pain
hypersensitivity [34–36], we next sought to determine if
the observed antiallodynic effects of the lipid mediator
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could be mediated via alterations in reactivity of spinal
microglia and/or astrocytes in mice after SCI. We used
the most common glial markers, including IBA-1 for
microglia and GFAP for astrocytes, to reveal SCI-induced
changes in spinal glial reactivity and their susceptibility to
treatment with LXA4. We performed IBA-1 and GFAP
immunohistochemistry on thoracic spinal cord sections
from mice 7 and 36 days post SCI (Fig. 3a, d, respectively).
We found that SCI induced remarkable changes in both
microglia and astrocytes, as revealed by increases in stain-
ing intensity of IBA-1 and GFAP in the spinal cord ipsilat-
eral to injury at 7 and 36 days (Fig. 3b, c, e, f ). Compared
to the vehicle-treated SCI group, IBA-1 staining in the
LXA4-treated SCI group was significantly decreased by
Fig. 3 LXA4 attenuates the SCI-induced microglial reactivity in the spinal cord. Lipoxin A4 reduces the SCI-induced increase in Iba-1 expression in the
spinal cord at 7 and 36 days after surgery. Staining for Iba-1 (red, a), GFAP (green, b), and DAPI (blue) in thoracic spinal cord from sham, vehicle-treated
SCI, or LXA4-treated SCI mice. Scale 200 μm. Iba-1 staining was enhanced at 7 (a, b) and 36 days (d, e) after SCI and was reduced by LXA4 treatment.
GFAP expression was significantly upregulated by SCI at 7 (a–c) and 36 days (d–f) but was not changed following LXA4 administration. Results shown
in graphs are presented as mean ± SEM. Asterisk denotes p < 0.05 when comparing to sham-operated group. Number sign denotes p < 0.05 when
comparing with vehicle-treated group (Student’s t test, n = 6 mice/group)
Fig. 2 ALX/FPR2 receptor gene knockdown with intrathecal siRNA treatment impairs the analgesic effect of LXA4 after SCI in mice. a No differences
were observed on the 7th day post-surgery with the siRNA administration in the ipsilateral paw. b Gene knockdown suppresses the antihyperalgesic
effects of LXA4 observed in the contralateral paw. c On the 7th day after surgery, there is a significant decrease on ALX/FPR2 receptor mRNA levels in
the spinal cord of animals injected with the specific siRNA. Results are presented as mean ± SEM. Asterisk denotes p < 0.05 when comparing to
control-siRNA-treated group (two-way ANOVA followed by Bonferroni, n = 6 mice/group)
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36.7 ± 1.3 % at 7 days and 27.0 ± 9.4 % at 36 days of
(Fig. 3b, e), but GFAP staining was not modified
(Fig. 3c, f ). In line with our present results, a recent
study demonstrated the expression of ALX/FPR2
receptors in both microglia and astrocytes and an
anti-inflammatory effect of LXA4 in CNS [37].
Lipoxin A4 reduces SCI-induced expression of microglial
markers and synthesis of pro-inflammatory mediators in
the spinal cord
To confirm the cellular effect and identify the molecular
target of LXA4 in the CNS, we screened the expression of
well-known glial markers and inflammatory mediators
7 days after SCI by qPCR. First, we verified that ALX/FPR2
was similarly expressed in thoracic spinal cords from mice
receiving a vehicle control or a LXA4 injection, supporting
comparable drug-receptor interactions in both conditions
(Fig. 4a). Furthermore, we confirmed the potential effect of
LXA4 on microglia but not astrocytes. Consistently, the
mRNA expression level of the astrocytic marker GAFP was
unaffected by LXA4 treatment (Fig. 4b), whereas microglial
markers IBA-1 and P2Y12 were significantly decreased in
mice treated with LXA4 when compared to vehicle-treated
mice (Fig. 4c). Microglia generally respond to injury by re-
leasing, for instance, cytokines, nitric oxide, and growth
factors [38–41]. Quantitative real-time RT-PCR analyses of
TNF-α, IL-6, iNOS, IL-10, and TGFβ in mice showed that
LXA4 treatment significantly decreased the transcriptional
expression of TNF-α compared to the control vehicle
treatment (Fig. 4d). Protein analyses of thoracic spinal
cords from rats not only confirmed the effect of LXA4 on
TNF-α expression levels but also revealed a significant
decrease in expression levels of IL-6 and IL-1β, suggesting
predominant post-transcriptional mechanisms for LXA4
action (Additional file 2: Figure S2A–C). Notably, LXA4
treatment did not affect the expression levels of the anti-
inflammatory cytokine IL-10 (Fig. 4e and Additional file 2:
Figure S2D) and of the growth factor TGFβ (Fig. 4e).
Altogether, these results suggest SCI-induced increases in
the microglial reactivity and synthesis of pro-inflammatory
cytokines near the injury is partially blocked by LXA4
treatment through a potential interaction of LXA4 with
microglial cells.
LXA4 inhibits TNF-α release in microglial cultures
To test a direct effect of LXA4 on microglial activation,
we sought to examine the effect of LXA4 in primary
microglia cultures. First, we verified the expression of the
ALX/FPR2 receptor in microglia culture by immunofluor-
escence (Fig. 5a) and by RT-PCR (Fig. 5b). Next, we acti-
vated microglia culture with 20 ng/ml of IFN-γ for 3 h,
since this cytokine can potently activate microglia and also
play a role in spinal pain processing [42]. To determine
whether LXA4 affects microglia activation, we examined
the phosphorylation of the p-38 mitogen-activating kinase
(p-p38), which is a critical step of microglia activation in
various neuropathic pain models [43–47]. There was a
significant increase of p-p38 in microglia subjected to
Fig. 4 Lipoxin A4 reduces the expression of microglial markers and TNF-α. a–h Spinal cord injury promotes a significant upregulation of ALX/
FPR2 receptors, GFAP, IBA-1, P2Y12, TNF-α, IL-6, iNOS, and TGF-β mRNA levels 7 days post-surgery, comparing to sham-operated mice. c–e LXA4
significantly reduced IBA-1, P2Y12, and TNF-α mRNA levels. Data is expressed as mean ± SEM. Asterisk denotes p < 0.05 when comparing to
sham-operated group. Number sign denotes p < 0.05 when comparing with vehicle-treated group (one-way ANOVA followed by Bonferroni;
n = 4 mice/group)
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IFN-γ, but this increase was abrogated in cultures treated
with 10 nM of LXA4 (Fig. 5c). Next, we tested if LXA4
treatment would abrogate IFN-γ-induced TNF-α release.
Similar to our in vivo results (Fig. 4d and Additional file 2:
Figure S2A), IFN-γ-induced microglial TNF-α release was
significantly decreased by LXA4 treatment, when com-
pared to the vehicle-treated controls (Fig. 5d). These in
vivo results indicate a direct effect of LXA4 on microglial
activation and TNF-α release.
Discussion
Spinal cord injury triggers neuroinflammation and
chronic pain. It is becoming increasingly apparent that
controlling SCI-induced neuroinflammation can improve
recovery from injury and neuropathic pain. However,
few drugs have been shown to be safe and efficient in
manipulating neuroinflammation and pain. Given the
safety profile and pro-resolution and analgesic properties
of the endogenous lipid mediators [13, 48–52], we inves-
tigated the potential anti-inflammatory and analgesic
roles of the lipid mediator LXA4 in a rodent model of
SCI. Our results clearly demonstrate that LXA4 effect-
ively attenuates microglial reactivity and neuropathic
pain after SCI.
We used an animal model of SCI consisting in thor-
acic spinal cord hemisection. Despite the partial nature
of this type of spinal cord section, this model conserves
several intact ascending and descending somatosensory
pathways [22, 53], in which maladaptive plasticity results
in neuropathic pain (i.e., mechanical allodynia in animal
hind paws). This model is also characterized by the de-
velopment of an extensive neuroinflammation around
the injury site, which is also observed in patients suffer-
ing from SCI [54, 55].
Current analgesic treatments for SCI, such as anticon-
vulsants and antidepressants, target specific neuronal
mechanisms and are mostly ineffective and accompanied
by severe side effects [56, 57]. Here, we show that LXA4,
an endogenous lipid mediator with no known toxicity, can
alleviate SCI-induced neuropathic pain. Fatty acids derived
from omega-3 and omega-6 have been previously involved
in SCI [58–61] and DHA, in particular, shown to display
promising analgesic effects [62]. Lipid mediators that are
metabolized from fatty acids (i.e., resolvins, protectins,
and lipoxins) generally have greater analgesic efficacy and
potency in various animal models of inflammatory and
neuropathic pain [7, 16, 17, 63, 64]. Indeed, we demon-
strated that two intrathecal injections of LXA4 in the
picomolar dose range were sufficient to alleviate mechan-
ical allodynia for up to 28 days after SCI.
LXA4 mostly acts on the G protein-coupled ALX/FPR2
receptor [65, 66], but LXA4 can also bind to additional
receptors, including the aryl hydrocarbon receptor, the
cysteinyl leukotriene receptor, the GPR32 receptor, and
the CB1 cannabinoid receptor [29, 67–70]. However, the
finding that knockdown of ALX/FPR2 receptor expression
with specific siRNA inhibited the analgesic effect of LXA4
indicates that this receptor is an important target for the
effects of the lipid seen in SCI animals.
Our results also showed that LXA4 reduced the SCI-
induced enhancement of reactivity of microglia and of
expression of pro-inflammatory cytokines. Because
spinal release of pro-inflammatory cytokines such as
TNFα, IL-6, and IL1β are critical for the pathogenesis of
Fig. 5 Lipoxin A4 attenuates microglial activation in primary cultures. a Microglia cells stained for DAPI (blue) and ALX/FPR2 receptor (red). Scale
50 μm. b Representative image of ALX/FPR2 mRNA expression on the spinal cord and microglia and astrocytes cultures. c LXA4 reduced p-p38
increase induced by IFN-γ. d IFN-γ induces a significant increase in TNF-α release, which is reduced by both concentrations of LXA4. Data is
expressed as mean ± SEM. Asterisk denotes p < 0.05 when comparing to control. Number sign denotes p < 0.05 when comparing with vehicle
(one-way ANOVA followed by Bonferroni; n = 4 cultures)
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pain [71–73], the anti-nociceptive effects of LXA4 could
be attributable to its anti-inflammatory role.
After SCI, TNF-α levels become elevated in the spinal
cord and may trigger pain hypersensitivity. Recently, we
have demonstrated that microglial TNF-α can rapidly
modulate synaptic transmission and pain hypersensitivity,
including mechanical hyperalgesia [74]. TNF-α is a key
pro-inflammatory pain mediator because it can influence
multiple mechanisms involved in pain transmission. It can
increase pre-synaptic pain transmission via activation of
TRPV1 in C-type primary afferent terminals [74, 75] and
also act on post-synaptic AMPA and NMDA receptors,
increasing synaptic transmission in excitatory neurons
[76, 77]. TNF-α can also decrease inhibitory synaptic
transmission in the spinal cord [78, 79], stimulate the
release of additional pro-inflammatory cytokines, and
induce proliferation of immune and glial cells to enhance
neuroinflammation and pain transmission [80]. For
instance, TNF-α elicits astrocytic proliferation and release
of pro-inflammatory and pronociceptive mediators [27].
Although we were unable to observe a diminishing ef-
fect of LXA4 treatment on the reactivity of astrocytes,
one cannot exclude that LXA4 may act directly on
astrocytes and reduce pro-inflammatory mediator
release from these cells.
We showed the expression of the ALX/FPR2 receptor in
primary microglial culture, and it has been previously
demonstrated that LXA4 can also act on astrocytes inhi-
biting their activation and alleviating pain hypersensitivity
in an animal model of inflammatory pain [15]. ALX/FPR2
receptors are found in a wide array of tissues, including
the peripheral nervous system, macrophages, and neutro-
phils [28, 81, 82]. Thus, the beneficial effects of LXA4
after SCI should not be attributed solely to the regulation
of astrocytes and microglia. However, we observed that
LXA4 specifically decreased SCI-induced overexpression
of microglial markers IBA-1 and P2Y12 in the spinal cord
in vivo and inhibited phosphorylation of p38 and release
of TNF-α in microglial culture stimulated by INF-γ, a
commonly used activator of microglia. To support our
data, the inhibition of microglial p-p38 by exogenous
LXA4 has been recently reported in an animal model of
hemorrhage [37]. In agreement with a role of microglia in
SCI-induced neuropathic pain, a previous study has
shown that spinal cord treatment with minocycline, a
widely used microglial inhibitor, can attenuate the hyper-
responsiveness of lumbar dorsal horn neurons and pain
hypersensitivity following SCI [83].
Interestingly, we observed that late LXA4 treatment (at
35 days after SCI) is still effective in reducing neuropathic
pain. A previous study showed that a treatment blocking
TNF-α release effectively reduced SCI-induced mechan-
ical hyperalgesia when given immediately after spinal cord
hemisection but was ineffective when delivered 2–3 weeks
after injury [84]. The analgesic effect of LXA4 in the late
phase may thus be independent of TNF-α. Lipid
mediators have multiple actions in addition to controlling
neuroinflammation. They are also involved in the reso-
lution of synaptic plasticity in the CNS and modulation of
TRP channel activities [7]. Further studies will be needed
to fully understand the mechanisms and appreciate the
therapeutic potentials of LXA4 in spinal cord injury.
Conclusions
Between 250 000 and 500 000 people become spinal cord
injured every year, and most of them develop chronic pain.
SCI is heterogeneous and characterized by neuronal apop-
tosis, demyelination, and neuroinflammation. Resident
and invading inflammatory cells (including microglia) are
associated with the development of persistent pain, and
these immune cells can have either destructive or repara-
tive roles after SCI. Collectively, our findings demon-
strated that LXA4 could alter pro-inflammatory responses
of microglia while sparing anti-inflammatory responses to
SCI and, importantly, promote effective and persistent
alleviation of mechanical allodynia. Given the potent
anti-inflammatory, pro-resolution, and analgesic effi-
cacy and safety profiles of LXA4, this endogenous lipid
mediator may constitute a new therapeutic tool for the
management of neuroinflammation and neuropathic
pain following spinal cord injury.
Additional files
Additional file 1: Figure S1. Lipoxin A4 reduces mechanical
allodynia induced by spinal cord hemisection in rats. A, C, Following
SCI, adult rats develop mechanical hypersensitivity in both ipsilateral
and contralateral hindpaws. Frequency of responses is reduced with
LXA4 administration, compared to vehicle-treated group. B, D, The area
under the curve of frequency of paw withdrawal responses to mechanical
stimulation of ipsilateral and contralateral paw over time. Results are presented
as mean ± SEM. * denotes p< 0.05 when comparing to sham-operated group.
# denotes p< 0.05 when comparing with vehicle-treated group (two-way
ANOVA followed by Bonferroni; n= 8 rats/group). (TIF 2197 kb)
Additional file 2: Figure S2. Lipoxin A4 reduces the expression of
pro-inflammatory cytokines in the rat spinal cord. A–C, Spinal cord injury
promotes a significant upregulation of IL-6, IL-1β, and TNF-α expression
in the spinal cord. The three cytokines are significantly reduced by LXA4,
in comparison to vehicle-treated group. D There is no significant change in
the IL-10 cytokine levels. Results are presented as mean ± SEM. * denotes
p < 0.05 when comparing to sham-operated group and # denotes p < 0.05
when comparing with vehicle-treated group (One-way ANOVA followed by
Bonferroni; n = 4 rats/group). (TIF 1262 kb)
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